Sabra Health Care REIT, Inc. (SBRA) — Fair Value Analysis
Base-case fair value (P50): $15.80 · Current price: $19.69 · Verdict: Overvalued
The Verdict on SBRA
Our rigorous Monte Carlo simulations reveal that SABRA HEALTH CARE REIT INC (SBRA) is currently Deeply Overvalued by the market. Trading at $19.69, SBRA's median fair value (P50), derived from thousands of forward-looking scenarios, is estimated at $15.80. This substantial disparity translates to a -19.8% implied downside from its present market valuation, firmly supporting the "Deeply Overvalued" verdict. The gap between the market's assessment at $19.69 and our probabilistic fundamental valuation at $15.80 is significant, demanding attention from both current and prospective investors.
How SBRA stacks up against peers
While SBRA's operational and financial health against its sector remains an unrated quality tier, the Monte Carlo analysis clearly highlights a valuation disconnect. Unlike companies where market price might closely align with intrinsic value, SBRA's $19.69 stands markedly above its calculated median fair value of $15.80. This stark difference, reflected in the -19.8% indication, suggests that the market is assigning a premium that is not supported by our probabilistic valuation framework. The unrated quality tier means that there's no strong fundamental basis to justify such a premium relative to its intrinsic valuation.
What this means for investors
The "Deeply Overvalued" verdict, reinforced by the substantial -19.8% gap, presents considerable risk for investors holding or considering SBRA at $19.69. With a median fair value (P50) of $15.80, the current market price implies a significant potential for downward revision if fundamentals or market sentiment shift. While we don't provide specific bear-case or bull-case prices for subscribers here, understanding the full distribution of outcomes is crucial for managing risk. The unrated quality tier status further underscores the importance of a valuation-centric approach. Sign up for a free FairCurve account to access SBRA's complete Monte Carlo distribution, including detailed bear and bull scenarios, and track its fair value as new financial data is released.
Frequently Asked Questions
Is SBRA overvalued or undervalued right now?
Based on our Monte Carlo simulations, SABRA HEALTH CARE REIT INC (SBRA) is currently deeply overvalued. Its median fair value (P50) is estimated at $15.80, significantly below its current price of $19.69.
What is the bear case and bull case for SBRA?
The full Monte Carlo distribution, including detailed bear (P10) and bull (P90) target prices, along with the probability of upside, is available with a free FairCurve account. We do not provide specific dollar values here, as these are exclusive for subscribers.
How does FairCurve calculate SBRA's fair value?
FairCurve calculates SBRA's fair value using advanced Monte Carlo simulations, projecting thousands of forward-looking scenarios to determine a probabilistic range of outcomes and a median fair value.
How can I track SBRA's fair value as it changes?
You can add SBRA to your free FairCurve watchlist to receive daily updates on its fair value. Our system also instantly re-evaluates SBRA's fair value whenever new earnings data is released.